TACSTD2 and pancreatic neoplasm: Among all pathogenic KRAS mutations, the prevalence of G12C was similar between TACSTD2-high versus TACSTD2-low groups in both CRC (7.3% vs 6.4%) and pancreatic cancer (1.5% vs 1.5%; P > .05; data not shown).